title: The effect of CaCl2 and verapamil on the binding of cisplatin to cultures of normal and transformed human fibroblasts.
abstract: Normal and transformed human fibroblasts were treated for either 1 sec or 1 h with the antitumor drug cis-dichlorodiamine platinum (cisplatin). The dose response of drug binding and cell survival was determined for cells treated with the drug in the presence or absence of 3.0 mM CaCl2. The levels of drug initially bound to both cell types was similar and was not affected by the presence of Ca2+. The dividing non-transformed cells were most sensitive to killing by short treatment with cisplatin compared to the transformed cells or the confluent non-transformed cultures. After 1 h of cisplatin treatment, the levels of drug bound to the cells were significantly less than that recovered after the shorter treatment. This time-dependent loss of cisplatin was inhibited both by CaCl2 and by the calcium channel blocking agent, verapamil. The higher levels of cisplatin bound after 1 h in the presence of these agents, however, did not in all cases result in decreased survival; the effects were dependent on cell type and on whether the cells were dividing or confluent. Analysis of cisplatin binding to cell cultures indicated that initially the cisplatin was weakly attached to the pericellular and substratum attached material but that with time, the drug bound to this material decreased. This time-dependent removal from the extracellular matrix was much less in the transformed cell cultures and was inhibited by calcium. We propose that the major site of interaction of cisplatin with these cells is in the extracellular matrix and with time the cultures alter their extracellular matrix to decrease this binding. This removal process appears to involve calcium or calcium transport since CaCl2 and verapamil both block these changes.
authors.affiliation: Department of Biochemistry, Michigan State University, East Lansing 48824.
authors.forename: B
authors.initials: B
authors.lastname: Hamel
authors.forename: S
authors.initials: S
authors.lastname: Malachowski
authors.forename: L
authors.initials: L
authors.lastname: Vancamp
authors.forename: E J
authors.initials: EJ
authors.lastname: McGroarty
mesh_terms: D002121:Calcium Channel Blockers / Q000494:pharmacology; D002122:Calcium Chloride / Q000494:pharmacology*; D002461:Cell Line, Transformed / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D002945:Cisplatin / Q000378:metabolism*; D005347:Fibroblasts / Q000378:metabolism*; D006801:Humans; D012965:Sodium Chloride / Q000494:pharmacology; D013997:Time Factors; D014700:Verapamil / Q000494:pharmacology*
chemical_list: D002121:Calcium Channel Blockers; D012965:Sodium Chloride; D014700:Verapamil; D002122:Calcium Chloride; D002945:Cisplatin